See the published version of this preprint at Malaria Journal.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
A new preprint design is coming!
We have improved readability, clarity, accessibility, and opportunities for engagement.
Research
Francine Ntoumi
Fondation Congolaise pour la Recherche Médicale
Corresponding Author
ORCiD: https://orcid.org/0000-0003-4748-050X
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background Malaria in pregnancy is associated with considerable morbidity and mortality. Regular surveillance of artemisinin−based combination therapy tolerance, or molecular makers of resistance, is vital for effective malaria treatment, control and eradication programmes. Plasmodium falciparum multiple drug resistance-1 gene (Pfmdr1) N86Y mutation is associated with reduced susceptibility to lumefantrine. This study assessed the prevalence of Pfmdr1 N86Y in Brazzaville, Republic of Congo.
Methods A total 1001 of P. falciparum-infected blood samples obtained from asymptomatic malaria pregnant women having a normal child delivery at the Madibou Integrated Health Centre were analysed. Pfmdr1 N86Y genotyping was conducted using PCR-restriction fragment length polymorphism.
Results The wild type Pfmdr1 N86 allele was predominant (>68 %) in this study, whereas a few isolates carrying the either the mutant allele (Pfmdr1 86Y) alone or both alleles (mixed genotype). The dominance of the wildtype allele (pfmdr1 N86) indicates the plausible decline P. falciparum susceptibility to lumefantrine.
Conclusion This study gives an update on the prevalence of Pfmdr1 N86Y alleles in Brazzaville, Republic of Congo. It also raises concern on the imminent emergence of resistance against artemether−lumefantrine in this setting. This study underscores the importance to regular artemether−lumefantrine efficacy monitoring to inform the malaria control programme of the Republic of Congo.
Keywords
Plasmodium falciparum, Pfmdr1, antimalarial drug resistance, lumefantrine, Brazzaville, Republic of Congo
Figure 1
Loading...
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Published
View the published article at Malaria Journal.
Version 4
Posted 07 May, 2020
No community comments so far
Editorial decision: Accept
On 25 Apr, 2020
No comments provided
Editorial decision: Minor revision
On 22 Apr, 2020
Editor assigned
On 20 Apr, 2020
Submission checks complete
On 19 Apr, 2020
Editor invited
On 19 Apr, 2020
No comments provided
Review #1 received
Received 31 Mar, 2020
Editorial decision: Minor Revision
On 31 Mar, 2020
Review #2 received
Received 19 Mar, 2020
Reviewer #2 agreed
On 01 Mar, 2020
Editor assigned
On 28 Feb, 2020
Reviewers invited
Invitations sent on 28 Feb, 2020
Reviewer #1 agreed
On 28 Feb, 2020
Submission checks complete
On 27 Feb, 2020
Editor invited
On 27 Feb, 2020
No comments provided
Editorial decision: Major Revision
On 24 Jan, 2020
Review #1 received
Received 04 Jan, 2020
Review #2 received
Received 04 Jan, 2020
Reviewer #2 agreed
On 20 Dec, 2019
Reviewer #1 agreed
On 20 Dec, 2019
Reviewers invited
Invitations sent on 19 Dec, 2019
Editor assigned
On 24 Nov, 2019
First submitted
On 23 Nov, 2019
Submission checks complete
On 23 Nov, 2019
Editor invited
On 23 Nov, 2019
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Infectious Diseases
Learn more about our company.
A new preprint design is coming!
We have improved readability, clarity, accessibility, and opportunities for engagement.
See the published version of this preprint at Malaria Journal.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research
Francine Ntoumi
Fondation Congolaise pour la Recherche Médicale
Corresponding Author
ORCiD: https://orcid.org/0000-0003-4748-050X
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Published
View the published article at Malaria Journal.
Version 4
Posted 07 May, 2020
No community comments so far
Editorial decision: Accept
On 25 Apr, 2020
No comments provided
Editorial decision: Minor revision
On 22 Apr, 2020
Editor assigned
On 20 Apr, 2020
Submission checks complete
On 19 Apr, 2020
Editor invited
On 19 Apr, 2020
No comments provided
Review #1 received
Received 31 Mar, 2020
Editorial decision: Minor Revision
On 31 Mar, 2020
Review #2 received
Received 19 Mar, 2020
Reviewer #2 agreed
On 01 Mar, 2020
Editor assigned
On 28 Feb, 2020
Reviewers invited
Invitations sent on 28 Feb, 2020
Reviewer #1 agreed
On 28 Feb, 2020
Submission checks complete
On 27 Feb, 2020
Editor invited
On 27 Feb, 2020
No comments provided
Editorial decision: Major Revision
On 24 Jan, 2020
Review #1 received
Received 04 Jan, 2020
Review #2 received
Received 04 Jan, 2020
Reviewer #2 agreed
On 20 Dec, 2019
Reviewer #1 agreed
On 20 Dec, 2019
Reviewers invited
Invitations sent on 19 Dec, 2019
Editor assigned
On 24 Nov, 2019
First submitted
On 23 Nov, 2019
Submission checks complete
On 23 Nov, 2019
Editor invited
On 23 Nov, 2019
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Infectious Diseases
License:
This work is licensed under a CC BY 4.0 License. Read Full License
View the published article at Malaria Journal.
Background Malaria in pregnancy is associated with considerable morbidity and mortality. Regular surveillance of artemisinin−based combination therapy tolerance, or molecular makers of resistance, is vital for effective malaria treatment, control and eradication programmes. Plasmodium falciparum multiple drug resistance-1 gene (Pfmdr1) N86Y mutation is associated with reduced susceptibility to lumefantrine. This study assessed the prevalence of Pfmdr1 N86Y in Brazzaville, Republic of Congo.
Methods A total 1001 of P. falciparum-infected blood samples obtained from asymptomatic malaria pregnant women having a normal child delivery at the Madibou Integrated Health Centre were analysed. Pfmdr1 N86Y genotyping was conducted using PCR-restriction fragment length polymorphism.
Results The wild type Pfmdr1 N86 allele was predominant (>68 %) in this study, whereas a few isolates carrying the either the mutant allele (Pfmdr1 86Y) alone or both alleles (mixed genotype). The dominance of the wildtype allele (pfmdr1 N86) indicates the plausible decline P. falciparum susceptibility to lumefantrine.
Conclusion This study gives an update on the prevalence of Pfmdr1 N86Y alleles in Brazzaville, Republic of Congo. It also raises concern on the imminent emergence of resistance against artemether−lumefantrine in this setting. This study underscores the importance to regular artemether−lumefantrine efficacy monitoring to inform the malaria control programme of the Republic of Congo.
Figure 1
Loading...